Posts from December, 2016 - VAR2 Pharmaceuticals

The role of oncofetal CSA is published in a major article Thursday, 01 December 2016

Poul Sorensen nominated as significant Contributor to Canada’s Innovative Healthcare Industry

Uncategorized 08 May 2019

On May 7th, Bloom Burton & Co. announced that VAR2 Pharmaceuticals' co-founder and member of the Board, Prof. Poul Sorensen, is one of the three final nominees to the prestigious 2019 Bloom B...

Research awarded St. Baldrick’s Foundation Grant

Uncategorized 05 May 2019

On May 3rd 2019 Co-founder and Chairman of the Board, Dr. Mads Daugaard, was awarded St. Baldrick’s Foundation Awards One-of-a-Kind Grant to Aid in Childhood Cancer Research Discovery f...

Best poster presentation at EMBO Cancer meeting!

Uncategorized 19 September 2018

It is with great pleasure we can announce that Dr. Nader Al-Nakouzi was awarded The FEBS Journal Best Poster Prize for the poster "Expression and regulation of oncofetal chondroitin sulfate in prostat...

Presentation of VAR2-based immunotherapy at the 9th CDD Conference on Cancer

Uncategorized 16 September 2018

Co-founder and executive Chairman of the Board of directors, Dr. Mads Daugaard, are to present data on VAR2-based immunotherapy in the context of the cancer microenvironemnt at the 9th CDD Confer...